🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🗣️Kidney Cancer Rapid Oral Abstracts #ASCO25 👉Abs4516: Dr Tian Zhang, MD, MHS presenting Step 1⃣ #PDIGREE Nivo/Ipi -> (SD/PR) Nivo vs Nivo/Cabo #ALLIANCE 🩺Clinical implications: - Step 1⃣ 33% stopped tx due to AEs (44%), PD (13%) - Step 2⃣ 67% pts registered PD (18.9%), SD/PR

🗣️Kidney Cancer Oral Abstracts #ASCO25 👉Abs4521: Dr #JAmesGeller presenting Nivo/Axitinib vs Nivo in pts with translocation RCC #AREN1721 🩺Clinical implications: - Nivo/Axitinib (n=6) showed early efficacy ORR 33% and mPFS 10mo - #TranslocationRCC remains a disease of unmet

🗣️Bladder Cancer Oral Abstracts #ASCO25 👉LBA4513: Dr #VitalyMargulis presenting padeliporfin vascular targeted photodynamic therapy (VTP) for low grade UTUC from ph3 #ENLIGHTED 🩺Clinical implications: - #ENLIGHTED shows #VTP has early efficacy and safety supporting accrual

🗣️Bladder Rapid Oral Abstracts #ASCO25 👉Abs4517: Dr Tom Powles presenting #Sasanlimab + BCG in high risk NMIBC #CREST 🩺Clinical implications: - #Sasanlimab + BCG (IND and MNT) improved EFS in ITT and subgroups of pts with BCG-naive, high-risk NMIBC ❓ How to approach

This is the #bougiest best that ASCO TECAG has ever been. When I came to #ASCO22 it was a tiny conference room with water🥤 and pretzels 🥨. What an outstanding job the #TECAG team has done! #ASCO25 Emre Yekedüz Dimitra R. Bakaloudi MD, MS, MPA Andrea Anampa-Guzmán (she/ella) Regina Barragan-Carrillo Corey Speers

🌟 Brilliant presentation by Sumanta K. Pal, MD, FASCO at #ASCO25! Genomic analysis from IMmotion010👉 High KIM-1/Teff shows longer DFS with adjuvant atezolizumab vs placebo 🙌 ASCO OncoAlert KidneyCAN

Who will be the heme/onc fellowship that is lucky to get Renee Maria Saliby ???? #ASCO25 ASCO

🗣️Bladder Cancer Oral Abstracts #ASCO25 👉Abs4500: Dr Michiel van der Heijden presenting Nivo/Ipi vs Gem/Carbo in cis-ineligible pts on #CheckMate901 💉NIVO+IPI -> Nivo up to 2yr (n = 221) 💉Gem+Carbo up to 6cycles (n = 224) ❌mOS 19.1 mo vs 13.2 mo (0.79, 0.61–1.01) ❌mPFS 5.3 mo vs

🗣️Bladder Cancer Oral Abstracts #ASCO25 👉Abs4501: Dr Jean Hoffman-Censits presenting maintenance Avelumab + sacituzumab govitecan (SG) vs avelumab #JAVELINBLADDERMEDLEY 💉1L platinum-based chemotherapy x 4-6 cycles 👉Avelumab + SG (n= 74) 👉Avelumab + pbo (n= 37) ✅

🗣️Bladder Cancer Oral Abstracts #ASCO25 👉Abs4502: Dr Shilpa Gupta presenting analysis of responders to EV/P vs chemo in #EV302 💉 EV+P (n=442) 💉 Chemo (n=444) ✅ ORR 67.5% with EV+P vs 44.2% with chemo ✅ CR 30.4% with EV+P vs 14.5% with chemo In pts with CR: ✅mPFS

🌟Happening now at #ASCO25!! Shilpa Gupta is presenting exploratory analysis of responders from EV-302 👉 Patients with CR had longer PFS & OS with EV+P 👇 #bladdercancer ASCO OncoAlert UroToday.com Uromigos

🗣️Bladder Cancer Oral Abstracts #ASCO25 👉 Dr Jacqueline T. Brown, MD with a thought provoking discussion "Breaking the Platinum Ceiling in Advanced Bladder Cancer" ❔Where does SG/Trop2 go from here? 👉Role in the nonmetastatic/variant histologies? GCSF prophylaxis is critical

🗣️Kidney Cancer Oral Abstracts #ASCO25 👉Abs4505: Dr Robert Motzer MD presenting 9⃣yr f/u Nivo/Ipi vs Sunitinib for 1L ccRCC #CheckMate214 ITT (n = 1096) ♦️96 mo PFS rate = (23% vs 9%) ♦️96 mo DOR rate = (48% vs 19%) ♦️108 mo OS rate = (31% vs 20%) ♦️mOS (53mo vs 38mo) (HR 0.71)

🗣️Kidney Cancer Oral Abstracts #ASCO25 👉Abs4506: Dr Toni Choueiri, MD presenting #Casdatifan + Cabo for refractory ccRCC #ARC20 n = 27 prior tx adjuv only (5/26), metastatic (1L 17/26; 2L 4/26). prior tx IO only (15/26), IO + TKI (11/26). median f/u = 2.9mo (0.1–6.8) ♦️ORR = 46%

🌟Great presentation by Chadi Hage Chehade at #ASCO25!! Utilization and timing of NGS in pts w/ 5 most common cancers in the US👉Many pts either don’t receive NGS or have the first NGS very late 👇ASCO OncoAlert Neeraj Agarwal, MD, FASCO Umang Swami Flatiron Health UroToday.com

🏔️ A standing ovation at #ASCO25 for Dr. Christopher Booth and the CHALLENGE (CO.21) trial. A 3-year structured exercise program post-chemo in stage II/III colon cancer: ✅ Improved OS (HR 0.63, p=0.022) ✅ 1 life saved for every 14 patients 💬 “Exercise is no longer just a QOL

🗣️Prostate Rapid Oral Abstract #ASCO25 👉Abst5018: Dr #RikkeLøvendahlEefsen presenting Nivo + Ipi + SBRT in mCRPC #CheckPRO 🔑 KEY TAKE AWAYS - Nivo + Ipi + SBRT showed PSA RR 21% and ORR 20% - Responses short duration with rPFS ~2mo - Treatment related SAE 30% 👥Neeraj Agarwal, MD, FASCO

🗣️Prostate Rapid Oral Abstract #ASCO25 👉Abst5019: Dr #StefanieZschaebitz presenting TALA + ENZA in #HRRmutated mCRPC #TALAPRO2 🔑 KEY TAKE AWAYS - TALA + ENZA benefit most pronounced for BRCA1/2, PALB2, CDK12 vs PBO + ENZA 👥Neeraj Agarwal, MD, FASCO silke gillessen Advanced Prostate Cancer Consensus Conference

🗣️Prostate Oral Abstract #ASCO25 👉Abst5001: Dr Nick James also on @Prof-Nick-James.bsky.social presenting #MMAI for benefit from ARPI in high risk M0 PCa #STAMPEDE 🤖Multimodal AI #MMAI algorithm (ArteraAI Prostate Test v1.2) High-risk M0 STAMPEDE (w/ H&E images& clinical data) >2/3 Risk Factors (T3-4,

To all IMGs out there, the path is long but very much possible and rewarding. Many will say you can’t do it, we’re here say you can! Nicole Mott CU Department of Surgery AJS Student and Resident Scholar (STARS) Committee IMG_stories Project IMG ™ Project IMG Network